)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Pulse Biosciences
Pulse Biosciences (PLSE) investor relations material
Pulse Biosciences 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary14 Jan, 2026
Strategic vision, leadership, and technology differentiation
Focused on delivering revolutionary therapies using exclusive nanosecond pulsed field ablation (nsPFA) technology, offering unique technical and clinical advantages over existing methods.
Targeting large clinical markets, including electrophysiology (EP), cardiac surgery, and benign thyroid nodule ablation, with initial prioritization of these segments.
Emphasizing capital efficiency and market entry through direct and partnership-based business models, including direct-to-consumer strategies.
Leadership and board comprise experienced medtech professionals and industry veterans, with recent additions strengthening governance.
Ended 2025 with ~$81 million in cash and no debt, with increased burn rate reflecting investment in strategic priorities.
Technology and intellectual property
nsPFA delivers non-thermal, irreversible energy in billionths of a second, enabling larger, faster, and safer ablations with minimized side effects.
Differentiates from first-generation PFA by using nanosecond pulses for deeper, more controlled lesions and improved workflow.
Patent portfolio includes over 250 issued and 180 pending patents globally, with significant new filings in 2025.
Expanded IP portfolio by 144 issued and pending patents in the past year, covering all aspects of nsPFA technology and delivery.
nPulse platform targets over $6B in initial U.S. addressable markets, expanding to $16B globally.
Market opportunities and clinical progress
Key markets include EP for atrial fibrillation, surgical cardiac ablation, and benign thyroid nodule treatment, with EP market opportunity exceeding $3B in the U.S.
Surgical cardiac ablation market valued at $1.8B, with nPulse expected to be the first PFA solution to market.
Benign thyroid market opportunity estimated at $1.3B annually, with potential to eliminate up to 150k thyroidectomies per year.
nsPFA platform addresses a $6 billion initial market, leveraging a universal generator for multiple applications.
Thyroid application is pioneering a new interventional market, while cardiac surgery and EP ablation target existing but underpenetrated segments.
Thyroid market creation strategy
nsPFA efficacy advantage over current PFA
Next catalyst for EP partnership discussions
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Pulse Biosciences earnings date
Q4 202527 Mar, 2026
Pulse Biosciences
Next Pulse Biosciences earnings date
Q4 202527 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Pulse Biosciences Inc. is a medical technology company that develops therapeutic devices based on its proprietary Nano-Pulse Stimulation (NPS) technology. This technology uses short, nanosecond-duration electrical pulses to treat cellular structures, offering potential applications in dermatology, oncology, and other medical fields. Pulse Biosciences' products are designed to provide non-invasive treatment options, with the goal of improving clinical outcomes for patients in various therapeutic areas. The company is headquartered in Hayward, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage